Archivo de categorías para "Participación en proyectos europeos de I+D"

Basque SME from the north of Spain wishes to complete a consortium with a partner from the health sector (clinicians) who have access to kidney biopsies and kidney transplant biopsies. The objective is the development of a clinical analytic

An innovative Turkish company specialized in additive manufacturing and medical 3D printing focuses on custom made implant production for craniomaxillofacial patients. Having several properties such as biodegradability, drug release mechanism etc. provides the advantages of a controlled mechanism for

A Swedish SME have developed a ground-based heating/cooling system as a source for climate control of an aircraft cabin that both lower energy and the electricity use. They are now looking for airports in Malta, Portugal, Iceland and/or Norway

A partnership led by an Italian operator with a consolidated experience in the education and integration of migrants, and including an Italian university and a national association of Italian municipalities, is preparing a proposal under the call AMIF-2020 AG-CALL-02

An international consortium, led by a French innovation agency, is preparing a proposal to answer the COS-TOURINN-2020-3-04 call. The current partners are seeking for other partners (clusters, business support centres, public authorities, etc.) with different backgrounds matching with proposal’s

Andalusian public agency dedicated to urban and housing policy will coordinate a project proposal to be submitted to the H2020 Green Deal call focused on the development of demonstrative interventions incorporating the most advanced and sustainable urban innovations. It

Basque company specialized in developing R&D turnkey solutions is looking for an industrial partner to complete a consortium under an H2020 European Green Deal call. A partner from the energy sector and capable of dealing with marketing and business

A biopharmaceutical SME from Turkey is developing a Eurostars proposal to profile MEIS oncogene in patient derived tumor organoids and xenografts models and outline the potential of the first-in-class MEIS inhibitors. Partners sought: A company and a university research

A Hungarian pharma/biotechnology R&D company is developing novel matrix metalloproteinase inhibitor small molecules for treatment of ischemic diseases, e.g. ischemic cardiac disease, such as e.g. acute myocardial infarction. The company seeks partners to further develop the molecules in a

A Hungarian pharma/biotechnology R&D company is developing novel microRNA therapeutic compounds for ischemic diseases, e.g. ischemic cardiac disease, such as acute myocardial infarction and post-infarction heart failure. The company seeks partners to further develop the microRNA compounds in a